Activation of PPARγ inNSCLC by TZDs has induced cell growth arrest and apoptosis [60, 61]and affects expression of genes such as PTEN, fibronectin, and integrin alpha 5[62–64].However, PPARγ ligands have shown effects on NSCLC cell lines that remainelusive to understand with our current notions of PPARγ mechanism of action.For instance, rosiglitazone inhibits cell growth by increasing phosphorylationof AMPKα and reducing phosphorylation of p70S6K.Treatment with PPARγ antagonist, GW9662, has no effect onAMPKα and p70S6K phosphorylation status [65]. The gene discussed is RPS6KB1; the disease is non-small cell lung carcinoma.